Pharmacy World and Science

, Volume 23, Issue 3, pp 93–97 | Cite as

Evaluation of vancomycin use in a large university‐affiliated hospital in eastern France in 1999

  • N. Floret
  • M. Thouverez
  • D. Talon
  • B. Thalamy
  • J.M. Estavoyer


Objective: In 1999, we conducted a retrospective drug utilization review to determine the volume and pattern of vancomycin use in a university‐affiliated hospital in eastern France. Methods: Total vancomycin use was determined and expressed as vancomycin courses per 100 admitted patients and defined daily doses (DDD) of vancomycin per 100 patient‐days. The indication for vancomycin use was classified as appropriate or inappropriate according to the guidelines issues by the HICPAC. Results: A total of 311 vancomycin courses were given, as 2098 DDD, giving crude incidences of 1.17 courses per 100 admitted patients and of 1.19 defined daily doses per 100 patient‐days. The frequency of appropriate courses was 66.7%. Of the 63 inappropriate courses of vancomycin, 39.7% and 28.6% were empiric therapy for nosocomial and community‐acquired infections, respectively, 20.6% and 6.3% were specific therapy for nosocomial and community‐acquired infections, respectively, and 4.7% were prophylactic. Conclusions: This study shows that vancomycin use in our hospital resulted in a lower selection pressure than has been reported for US university‐affiliated hospitals and that comprehensive programs to improve use of vancomycin are needed in our institution.

Appropriate use Empirical therapy Glycopeptide resistance Hospital pharmacy Specific therapy Vancomycin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin – United States, 1989-1993. MMWR 1993;42:597-9.Google Scholar
  2. 2.
    Roghmann MC, Perdue BE, Polish L. Vancomycin use in a hospital with vancomycin restriction. Infect Control Hosp Epidemiol 1999;20:60-3.Google Scholar
  3. 3.
    Morris JG Jr, Shay DK, Hebden JN, McCarter RJ Jr, Perdue BE, Jarvis W, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Met 1995;123:250-9.Google Scholar
  4. 4.
    Lam S, Singer C, Tucci V, Morthland VH, Pfaller MA, Isenberg HD. The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study. Am J Infect Control 1995;23:170-80.Google Scholar
  5. 5.
    Wells CL, Juni BA, Cameron SB, Mason KR, Dunn DL, Ferrieri P, et al. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalised medical and/or surgical patients. Clin Infect Dis 1995;21:45-50.Google Scholar
  6. 6.
    Wade JJ. The emergence of Enterococcus faecium resistant to glycopeptides and other standard agents – a preliminary report. J Hosp Infect 1995;30 (suppl.):483-93.Google Scholar
  7. 7.
    Boyce JM, Mermel LA, Zervos MJ, Rice LB, Potter-Bynoe G, Giorgio C, et al. Controlling vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1995;16:634-7.Google Scholar
  8. 8.
    Noskin GA, Cooper I, Peterson LR. Vancomycin-resistant Enterococcus faecium sepsis following persistent colonization. Arch Intern Med 1995;155:1445-7.Google Scholar
  9. 9.
    Karanfil LV, Murphy M, Josephson A, Gaynes R, Mandel L, Hill BC, et al. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 1992;13:195-200.Google Scholar
  10. 10.
    Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105-113.Google Scholar
  11. 11.
    Handwerger S, Raucher B, Altarac D, Monka H, Marchione S, Singh KV, et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 1993;16:750-5.Google Scholar
  12. 12.
    Shlaes DM, Gerding DN, John JF Jr, Craig WA, Bornstein DL, Duncan RA, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997;18:275-91.Google Scholar
  13. 13.
    Van der Auwera P, Pensart N, Korten V, Murray BE, Leclerq R. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis 1996;173:1129-36.Google Scholar
  14. 14.
    Shay DK, Maloney SA, Montecalvo M, Banerjee S, Wormser GP, Arduino MJ, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995;172:993-1000.Google Scholar
  15. 15.
    Frieden TR, Munsiff SS, Low DE, Willey BM, Williams G, Faur Y, et al. Emergence of vancomycin-resistant enterococci in New York city. Lancet 1993;342:76-9.Google Scholar
  16. 16.
    Bertrand X, Thouverez M, Bailly P, Cornette C, Talon D and members of Réseau Franc-Comtois de Lutte contre les Infections Nosocomiales. Clinical and molecular epidemiology of hospital Enterococcus faecium isolates in eastern France. J Hosp Infect 2000;45:125-34.Google Scholar
  17. 17.
    Singer MV, Haft R, Barlam T, Aronson M, Shafer A, Sands KE. Vancomycin control measures at a tertiary-care hospital: impact of interventions on volume and patterns of use. Infect Control Hosp Epidemiol 1998;19:248-53.Google Scholar
  18. 18.
    Amsden GW, Schentag JJ. Tables of antimicrobial agent pharmacology. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1995:492-528.Google Scholar
  19. 19.
    Evans ME, Millheim ET, Rapp RP. Vancomycin use in a university medical center: effect of a vancomycin continuation form. Infect Control Hosp Epidemiol 1999;20:417-20.Google Scholar
  20. 20.
    Angim AM, Klym B, Byers BE, Scheld WM, Farr BM. Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin resistant Enterococcus faecium. Arch Intern Med. 1997;157:1132-6.Google Scholar
  21. 21.
    Watanakunakorn C. Prescribing pattern of vancomycin in a community teaching hospital with low prevalence of vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1997;18:767-9.Google Scholar
  22. 22.
    Logsdon BA, Lee KR, Luedtke G, Barrett FF. Evaluation of vancomycin use in a pediatric teaching hospital based on CDC criteria. Infect Control Hosp Epidemiol 1997;18:780-2.Google Scholar
  23. 23.
    Ena J, Dick RW, Jones RN, Wenzel RP. The epidemiology of intravenous vancomycin usage in a university hospital. JAMA 1993;269:598-602.Google Scholar
  24. 24.
    Morgan AS, Brennan PJ, Fishman NO. Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus. Ann Pharmacother 1997;31:970-3.Google Scholar
  25. 25.
    Sinkowitz RL, Keyserling HI, Walker TJ, Jarvis WR. The epidemiology of vancomycin usage at a children's hospital, 1993-1995. J Ped Infect Dis 1997;16:485-9.Google Scholar
  26. 26.
    Jarvis WR. Epidemiology, appropriateness, and cost of vancomycin use. Clin Infect Dis 1998;26:1200-3.Google Scholar
  27. 27.
    French GL. Enterococci and vancomycin resistance. Clin Infect Dis 1998, 27(Suppl. 1):S75-S83.Google Scholar
  28. 28.
    Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996,23:1020-5.Google Scholar
  29. 29.
    McGowan JE. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Infect 1994;7:478-83.Google Scholar
  30. 30.
    Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990;34:1227-31.Google Scholar
  31. 31.
    Cantoni L, Glauser MP, Bille J. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother 1990;34:2348-53.Google Scholar
  32. 32.
    Garrets JC, Worst WD, Silkey B, Gagnon S. A pharmacoeconomic model to evaluate antibiotic costs. Pharmacotherapy 1994;14:438-45.Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • N. Floret
    • 1
  • M. Thouverez
    • 1
  • D. Talon
    • 1
  • B. Thalamy
    • 2
  • J.M. Estavoyer
    • 3
  1. 1.Service d'Hygiène HospitalièreCHU BesançonFrance
  2. 2.Pharmacie CentraleCHU BesançonFrance
  3. 3.Service des Maladies Infectieuses et tropicalesCHU BesançonFrance

Personalised recommendations